Original articleEffect of oral Ursodeoxycholic acid (cas 128-13-2) on cholelithiasis following laparoscopic sleeve gastrectomy for morbid obesity
-
Add time:10/01/2019 Source:sciencedirect.com
BackgroundLaparoscopic sleeve gastrectomy (LSG) is a definitive solution for morbid obesity and its related co-morbidities. Cholelithiasis is a postoperative complication of LSG. The use of Ursodeoxycholic acid (cas 128-13-2) (UDCA) after LSG is a proposed solution to reduce the incidence of cholelithiasis.
We also recommend Trading Suppliers and Manufacturers of Ursodeoxycholic acid (cas 128-13-2). Pls Click Website Link as below: cas 128-13-2 suppliers
Prev:Ursodeoxycholic acid (cas 128-13-2) is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH
Next:Research ArticleUrsodeoxycholic acid (cas 128-13-2) therapy and liver transplant-free survival in patients with primary biliary cholangitis) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research ArticleUrsodeoxycholic acid (cas 128-13-2) therapy and liver transplant-free survival in patients with primary biliary cholangitis09/28/2019
- Ursodeoxycholic acid (cas 128-13-2) is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH09/27/2019
- Enzymatic routes for the synthesis of Ursodeoxycholic acid (cas 128-13-2)09/26/2019
- ArticlesUrsodeoxycholic acid (cas 128-13-2) versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial09/25/2019
- Original articleAdherence to Ursodeoxycholic acid (cas 128-13-2) therapy in patients with cholestatic and autoimmune liver disease09/24/2019
- Anticholestatic mechanisms of Ursodeoxycholic acid (cas 128-13-2) in lipopolysaccharide-induced cholestasis09/10/2019
- Ursodeoxycholic acid (cas 128-13-2) and cancer: From chemoprevention to chemotherapy09/09/2019
-
Health and Chemical more >